A Worldwide Phase III Clinical Trial Seeks U.S. Patients to Explore Investigational Drug P...( OVATUREtrial.com Launched to Inform ...),Health

OVATUREtrial.com Launched to Inform Patients with Recurrent Ovarian Cancer

about the OVATURE Clinical Research Study

NEW CANAAN, Conn., Aug. 30 /PRNewswire-FirstCall/ -- A new website has been launched to facilitate recruitment of patients to OVATURE (OVArian TUmor REsponse), a Phase III clinical trial of an investigational ovarian cancer drug phenoxodiol. The goal of http://www.OVATUREtrial.com is to inform ovarian cancer patients about the OVATURE trial, which is actively recruiting patients, and to provide more information about the trial and the investigational drug phenoxodiol. Visitors to the site will find information about the trial including eligibility, trial locations and participating doctors.

Hospitals and treatment centers throughout the United States, Europe and Australia are serving as trial sites, and http://www.OVATUREtrial.com will guide patients to site locations as they begin recruiting. Ovarian cancer patients whose cancer initially responded to chemotherapy, but has since become resistant or refractory to traditional platinum treatments are eligible to participate.

In the U.S. 30 sites are planned and the current trial locations include Yale University School of Medicine in New Haven, Connecticut; the Women's Cancer Center of Nevada in Las Vegas, Nevada; the University of Texas Southwestern Medical Center at Dallas in Dallas, Texas; Providence Hospital and Medical Centers in Southfield, Michigan; Hematology Oncology in Stamford, Connecticut; Gabrail Cancer Center in Canton, Ohio; Northern Virginia Pelvic Surgery Associates in Annandale, Virginia; and Chattanooga GYN Oncology in Chattanooga, Tennessee.

In Australia, the current trial locations include Prince of Wales Hospital and Westmead Hospital in Sydney; Royal Adelaide Hospital, in Adelaide; and Mater Adult Hospital in Brisbane. In E
'/>"/>